請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6537
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 阮雪芬 | |
dc.contributor.author | Yi-Hsuan Wu | en |
dc.contributor.author | 吳怡萱 | zh_TW |
dc.date.accessioned | 2021-05-17T09:14:30Z | - |
dc.date.available | 2017-08-28 | |
dc.date.available | 2021-05-17T09:14:30Z | - |
dc.date.copyright | 2012-08-28 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-15 | |
dc.identifier.citation | 1. Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M., GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No10. 2010. Available at globocan. iarc. fr.
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E., Cancer statistics, 2010. CA. Cancer J. Clin. 2010, 60 (5), 277-300. 3. Amann, A.; Corradi, M.; Mazzone, P.; Mutti, A., Lung cancer biomarkers in exhaled breath. Expert Rev. Mol. Diagn. 2011, 11 (2), 207-17. 4. (a) Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304 (5676), 1497-500; (b) Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L., EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (36), 13306-11; (c) Pao, W.; Miller, V. A., Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small-cell lung cancer: Current knowledge and future directions. J. Clin. Oncol. 2005, 23 (11), 2556-68. 5. (a) Jackman, D. M.; Yeap, B. Y.; Sequist, L. V.; Lindeman, N.; Holmes, A. J.; Joshi, V. A.; Bell, D. W.; Huberman, M. S.; Halmos, B.; Rabin, M. S., Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer. Res. 2006, 12 (13), 3908-14; (b) Riely, G. J.; Pao, W.; Pham, D. K.; Li, A. R.; Rizvi, N.; Venkatraman, E. S.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Miller, V. A., Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer. Res. 2006, 12 (3), 839-44. 6. (a) Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch Jr, T. J.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer. JAMA, J. Am. Med. Assoc. 2003, 290 (16), 2149-58; (b) Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J. Clin. Oncol. 2003, 21 (12), 2237-46. 7. (a) Moser, T. L.; Stack, M. S.; Asplin, I.; Enghild, J. J.; Hojrup, P.; Everitt, L.; Hubchak, S.; Schnaper, H. W.; Pizzo, S. V., Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (6), 2811-6; (b) Moser, T. L.; Kenan, D. J.; Ashley, T. A.; Roy, J. A.; Goodman, M. D.; Misra, U. K.; Cheek, D. J.; Pizzo, S. V., Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (12), 6656-61. 8. Chang, S. Y.; Park, S. G.; Kim, S.; Kang, C. Y., Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase. Its functional implication in endothelial cell proliferation. J. Biol. Chem. 2002, 277 (10), 8388-94. 9. Arakaki, N.; Nagao, T.; Niki, R.; Toyofuku, A.; Tanaka, H.; Kuramoto, Y.; Emoto, Y.; Shibata, H.; Magota, K.; Higuti, T., Possible role of cell surface H+ -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol. Cancer Res. 2003, 1 (13), 931-9. 10. Osanai, T.; Tanaka, M.; Kamada, T.; Nakano, T.; Takahashi, K.; Okada, S.; Sirato, K.; Magota, K.; Kodama, S.; Okumura, K., Mitochondrial coupling factor 6 as a potent endogenous vasoconstrictor. J. Clin. Invest. 2001, 108 (7), 1023-30. 11. Martinez, L. O.; Jacquet, S.; Esteve, J. P.; Rolland, C.; Cabezon, E.; Champagne, E.; Pineau, T.; Georgeaud, V.; Walker, J. E.; Terce, F., Ectopic β-chain of ATP synthase is an apolipoprotein AI receptor in hepatic HDL endocytosis. Nature 2003, 421 (6918), 75-9. 12. (a) Das, B.; Mondragon, M. O.; Sadeghian, M.; Hatcher, V. B.; Norin, A. J., A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. J. Exp. Med. 1994, 180 (1), 273-81; (b) Scotet, E.; Martinez, L. O.; Grant, E.; Barbaras, R.; Jeno, P.; Guiraud, M.; Monsarrat, B.; Saulquin, X.; Maillet, S.; Esteve, J. P., Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005, 22 (1), 71-80. 13. Huang, T. C.; Chang, H. Y.; Hsu, C. H.; Kuo, W. H.; Chang, K. J.; Juan, H. F., Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J. Proteome Res. 2008, 7 (4), 1433-44. 14. Arakaki, N.; Kita, T.; Shibata, H.; Higuti, T., Cell-surface H+-ATP synthase as a potential molecular target for anti-obesity drugs. FEBS Lett. 2007, 581 (18), 3405-9. 15. Kim, B. W.; Choo, H. J.; Lee, J. W.; Kim, J. H.; Ko, Y. G., Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts. Exp. Mol. Med. 2004, 36 (5), 476-85. 16. Burrell, H. E.; Wlodarski, B.; Foster, B. J.; Buckley, K. A.; Sharpe, G. R.; Quayle, J. M.; Simpson, A. W. M.; Gallagher, J. A., Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface. J. Biol. Chem. 2005, 280 (33), 29667-76. 17. Ohta, T.; Ikemoto, Y.; Usami, A.; Koide, T.; Wakabayashi, S., High affinity interaction between histidine-rich glycoprotein and the cell surface type ATP synthase on T-cells. Biochim. Biophys. Acta, Biomembr. 2009, 1788 (5), 1099-107. 18. Lyly, A.; Marjavaara, S. K.; Kyttala, A.; Uusi-Rauva, K.; Luiro, K.; Kopra, O.; Martinez, L. O.; Tanhuanpaa, K.; Kalkkinen, N.; Suomalainen, A., Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism. Hum. Mol. Genet. 2008, 17 (10), 1406-17. 19. Hong, S.; Pedersen, P. L., ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol. Mol. Biol. Rev. 2008, 72 (4), 590-641. 20. (a) Ueno, Y., Citreoviridin from Penicillium citreo-viride Biourge. Mycotoxins 1974, Edited by I. F. H. Purchasc. p283. Elsevier, New York; (b) K., U., Yellowed rice toxins. IV. Citreoviridin. Microb. Toxins 1971, 6, 367. Fungal Toxins. Edited by A. Ciegler, S. Kadis & S. Ajl. Academic Press, New York. 21. Hirata, Y., On the products of mould. I Poisonous substance from mouldy Rice (Part I) extraction (in Japanese). Journal of Chemical Society Japan 1947, 65, 63. 22. (a) Sakabe, N.; Goto, T.; Hirata, Y., Structure of citreoviridin, a mycotoxin produced by penicillium citreo-viride molded on rice. Tetrahedron 1977, 33 (23), 3077-81; (b) Sakabe, N.; Goto, T.; Hirata, Y., The structure of citreoviridin, a toxic compound produced by P. citreoviride molded on rice. Tetrahedron Lett. 1964, 5 (27), 1825-30. 23. Furusaki, A.; Watanabe, T.; Sakabe, N.; Hirata, Y., 22nd Ann Meet Chem. Soc. Japan 1969, (Tokyo). 24. Nagel, D. W.; Steyn, P. S.; Scott, D. B., Production of citreoviridin by Penicillium pulvillorum. Phytochemistry 1972, 11 (2), 627-30. 25. Linnett, P. E.; Mitchell, A. D.; Osselton, M. D.; Mulheirn, L. J.; Beechey, R. B., Citreoviridin, a specific inhibitor of the mitochondiral adenosine triphosphatase. Biochem. J. 1978, 170 (3), 503-10. 26. (a) Gause, E. M.; Buck, M. A.; Douglas, M. G., Binding of citreoviridin to the beta subunit of the yeast F1-ATPase. J. Biol. Chem. 1981, 256 (2), 557-9; (b) Satre, M.; Bof, M.; Vignais, P. V., Interaction of Escherichia coli adenosine triphosphatase with aurovertin and citreoviridin: inhibition and fluorescence studies. J. Bacteriol. 1980, 142 (3), 768-76. 27. (a) Datta, S. C.; Ghosh, J. J., Effect of citreoviridin, a toxin from Penicillium citreoviride NRRL 2579, on glycogen metabolism of rat brain. Toxicon 1981, 19 (2), 217-22; (b) Subhash C. Datta, J. J. G., Effect of treatment with citreoviridin, a neurotoxin of Penicillium citreoviride, on some enzymes of rat liver. Asian J. pharm. Sci. 1981, 1 (119); (c) Datta, S. C.; Ghosh, J. J., Production and purification of Penicillium citreoviride toxin and its effect on TPP-dependent liver transketolase. Folia Microbiol. 1981, 26 (5), 408-12. 28. Wilkins, M. R.; Pasquali, C.; Appel, R. D.; Ou, K.; Golaz, O.; Sanchez, J. C.; Yan, J. X.; Gooley, A. A.; Hughes, G.; Humphery-Smith, I., From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and arnino acid analysis. Nat. Biotechnol. 1996, 14 (1), 61-5. 29. Cox, J.; Mann, M., Quantitative, high-resolution proteomics for data-driven systems biology. Annu. Rev. Biochem. 2011, 80, 273-99. 30. (a) Aebersold, R.; Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422 (6928), 198-207; (b) Domon, B.; Aebersold, R., Mass spectrometry and protein analysis. Science 2006, 312 (5771), 212-7; (c) Cravatt, B. F.; Simon, G. M.; Yates Iii, J. R., The biological impact of mass-spectrometry-based proteomics. Nature 2007, 450 (7172), 991-1000; (d) Choudhary, C.; Mann, M., Decoding signalling networks by mass spectrometry-based proteomics. Nat. Rev. Mol. Cell Biol. 2010, 11 (6), 427-39; (e) Nilsson, T.; Mann, M.; Aebersold, R.; Yates, J. R.; Bairoch, A.; Bergeron, J. J. M., Mass spectrometry in high-throughput proteomics: ready for the big time. Nat. Methods 2010, 7 (9), 681-5; (f) Mallick, P.; Kuster, B., Proteomics: a pragmatic perspective. Nat. Biotechnol. 2010, 28 (7), 695-709. 31. Fenn, J. B.; Mann, M.; Meng, C. K.; Wong, S. F.; Whitehouse, C. M., Electrospray ionization for mass spectrometry of large biomolecules. Science 1989, 246 (4926), 64-71. 32. Ahrens, C. H.; Brunner, E.; Qeli, E.; Basler, K.; Aebersold, R., Generating and navigating proteome maps using mass spectrometry. Nat. Rev. Mol. Cell Biol. 2010, 11 (11), 789-801. 33. Ross, P. L.; Huang, Y. N.; Marchese, J. N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3 (12), 1154-69. 34. Hanahan, D.; Weinberg, R. A., Hallmarks of cancer: the next generation. Cell 2011, 144 (5), 646-74. 35. Kyung Kwon, Y.; Vander Heiden, M. G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell. Dev. Biol. 2011, 27 (1), 441-64. 36. (a) Warburg, O., On the origin of cancer cells. Science 1956, 123 (3191), 309-14; (b) Warburg, O.; Posener, K.; Negelein, E., Ueber den stoffwechsel der tumoren. Biochem. Z. 1924, 152, 319-44. 37. (a) Hume, D. A.; Weidemann, M. J., Role and regulation of glucose metabolism in proliferating cells. J. Natl. Cancer Inst. 1979, 62 (1), 3-8; (b) Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324 (5930), 1029-33. 38. Colell, A.; Green, D. R.; Ricci, J. E., Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ. 2009, 16 (12), 1573-81. 39. (a) Chen, Y. C.; Hsu, H. S.; Chen, Y. W.; Tsai, T. H.; How, C. K.; Wang, C. Y.; Hung, S. C.; Chang, Y. L.; Tsai, M. L.; Lee, Y. Y., Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 2008, 3 (7), e2637; (b) Lee, J.; Kim, H. K.; Han, Y. M.; Kim, J., Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 2008, 40 (5), 1043-54. 40. Daly, E. B.; Wind, T.; Jiang, X. M.; Sun, L.; Hogg, P. J., Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochim. Biophys. Acta, Mol. Cell Res. 2004, 1691 (1), 17-22. 41. (a) Koukourakis, M. I.; Giatromanolaki, A.; Harris, A. L.; Sivridis, E., Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006, 66 (2), 632-7; (b) Gillies, R. J.; Gatenby, R. A., Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 2007, 26 (2), 311-7; (c) Swietach, P.; Vaughan-Jones, R. D.; Harris, A. L., Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007, 26 (2), 299-310. 42. (a) Barthel, A.; Okino, S. T.; Liao, J.; Nakatani, K.; Li, J.; Whitlock Jr, J. P.; Roth, R. A., Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J. Biol. Chem. 1999, 274 (29), 20281-6; (b) Frauwirth, K. A.; Riley, J. L.; Harris, M. H.; Parry, R. V.; Rathmell, J. C.; Plas, D. R.; Elstrom, R. L.; June, C. H.; Thompson, C. B., The CD28 signaling pathway regulates glucose metabolism. Immunity 2002, 16 (6), 769-77; (c) Vander Heiden, M. G.; Plas, D. R.; Rathmell, J. C.; Fox, C. J.; Harris, M. H.; Thompson, C. B., Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001, 21 (17), 5899-912. 43. Gottlob, K.; Majewski, N.; Kennedy, S.; Kandel, E.; Robey, R. B.; Hay, N., Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Science 2001, 15 (11), 1406-18. 44. Semenza, G. L., HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20 (1), 51-6. 45. (a) Osthus, R. C.; Shim, H.; Kim, S.; Li, Q.; Reddy, R.; Mukherjee, M.; Xu, Y.; Wonsey, D.; Lee, L. A.; Dang, C. V., Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 2000, 275 (29), 21797-800; (b) Ahuja, P.; Zhao, P.; Angelis, E.; Ruan, H.; Korge, P.; Olson, A.; Wang, Y.; Jin, E. S.; Jeffrey, F. M.; Portman, M., Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J. Clin. Invest. 2010, 120 (5), 1494-505. 46. (a) Marsin, A. S.; Rider, M. H.; Deprez, J.; Beauloye, C., Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 2000, 10 (20), 1247-55; (b) Almeida, A.; Moncada, S.; Bolanos, J. P., Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat. Cell Biol. 2003, 6 (1), 45-51. 47. (a) Cheung, E. C.; Vousden, K. H., The role of p53 in glucose metabolism. Curr. Opin. Cell Biol. 2010, 22 (2), 186-91; (b) Levine, A. J.; Puzio-Kuter, A. M., The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330 (6009), 1340-4. 48. Lin, W. T.; Hung, W. N.; Yian, Y. H.; Wu, K. P.; Han, C. L.; Chen, Y. R.; Chen, Y. J.; Sung, T. Y.; Hsu, W. L., Multi-Q: a fully automated tool for multiplexed protein quantitation. J. Proteome Res. 2006, 5 (9), 2328-38. 49. Chu, Y. W.; Yang, P. C.; Yang, S. C.; Shyu, Y. C.; Hendrix, M. J.; Wu, R.; Wu, C. W., Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 1997, 17 (3), 353-60. 50. Han, C. L.; Chien, C. W.; Chen, W. C.; Chen, Y. R.; Wu, C. P.; Li, H.; Chen, Y. J., A Multiplexed Quantitative Strategy for Membrane Proteomics. Mol. Cell. Proteomics 2008, 7 (10), 1983-97. 51. (a) Sherman, B. T.; Lempicki, R. A., Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37 (1), 1-13; (b) Da Wei Huang, B. T. S.; Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2008, 4 (1), 44-57. 52. Nesvizhskii, A. I.; Aebersold, R., Interpretation of shotgun proteomic data. Mol. Cell. Proteomics 2005, 4 (10), 1419-40. 53. Moran, M. F.; Tong, J.; Taylor, P.; Strumpf, D.; Ignatchenko, V.; Pham, N. A.; Yanagawa, N.; Liu, G.; Jurisica, I.; Shepherd, F. A., Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. J. Proteome Res. 2011, 10 (1), 161-74. 54. (a) Orazine, C. I.; Hincapie, M.; Hancock, W. S.; Hattersley, M.; Hanke, J. H., A proteomic analysis of the plasma glycoproteins of a MCF-7 mouse xenograft: a model system for the detection of tumor markers. J. Proteome Res. 2008, 7 (4), 1542-54; (b) Tang, H. Y.; Beer, L. A.; Chang-Wong, T.; Hammond, R.; Gimotty, P.; Coukos, G.; Speicher, D. W., A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J. Proteome Res. 2012, 11 (2), 678-91. 55. (a) Burg, M. B.; Kwon, E. D.; KUltz, D., Regulation of gene expression by hypertonicity. Annu. Rev. Physiol. 1997, 59 (1), 437-55; (b) Yancey, P. H.; Clark, M. E.; Hand, S. C.; Bowlus, R. D.; Somero, G. N., Living with water stress: evolution of osmolyte systems. Science 1982, 217 (4566), 1214-22. 56. (a) Plas, D. R.; Talapatra, S.; Edinger, A. L.; Rathmell, J. C.; Thompson, C. B., Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J. Biol. Chem. 2001, 276 (15), 12041-8; (b) Rathmell, J. C.; Fox, C. J.; Plas, D. R.; Hammerman, P. S.; Cinalli, R. M.; Thompson, C. B., Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003, 23 (20), 7315-28; (c) Elstrom, R. L.; Bauer, D. E.; Buzzai, M.; Karnauskas, R.; Harris, M. H.; Plas, D. R.; Zhuang, H.; Cinalli, R. M.; Alavi, A.; Rudin, C. M., Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64 (11), 3892-9. 57. (a) Gordan, J. D.; Simon, M. C., Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 2007, 17 (1), 71-7; (b) Semenza, G. L., Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3 (10), 721-32. 58. (a) O'rourke, J. F.; Pugh, C. W.; Bartlett, S. M.; Ratcliffe, P. J., Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. EJBio 1996, 241 (2), 403-10; (b) Semenza, G. L.; Roth, P. H.; Fang, H. M.; Wang, G. L., Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269 (38), 23757-63. 59. (a) Cramer, T.; Yamanishi, Y.; Clausen, B. E.; Forster, I.; Pawlinski, R.; Mackman, N.; Haase, V. H.; Jaenisch, R.; Corr, M.; Nizet, V., HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003, 112 (5), 645-57; (b) Jiang, B. H.; Jiang, G.; Zheng, J. Z.; Lu, Z.; Hunter, T.; Vogt, P. K., Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12 (7), 363-9; (c) Majumder, P. K.; Febbo, P. G.; Bikoff, R.; Berger, R.; Xue, Q.; McMahon, L. M.; Manola, J.; Brugarolas, J.; McDonnell, T. J.; Golub, T. R., mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10 (6), 594-601. 60. Bensaad, K.; Tsuruta, A.; Selak, M. A.; Vidal, M.; Nakano, K.; Bartrons, R.; Gottlieb, E.; Vousden, K. H., TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126 (1), 107-20. 61. (a) Gold, J., Cancer cachexia and gluconeogenesis. Ann. N. Y. Acad. Sci. 1974, 230 (1), 103-10; (b) Leij-Halfwerk, S.; Dagnelie, P. C.; van den Berg, J. W. O.; Wattimena, J. D. L.; Hordijk-Luijk, C. H.; Wilson, J. H. P., Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. Am. J. Clin. Nutr. 2000, 71 (2), 583-9. 62. Wang, B.; Hsu, S. H.; Frankel, W.; Ghoshal, K.; Jacob, S. T., Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating Glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012, 56 (1), 186-97. 63. Whitehead, T. L.; Kieber-Emmons, T., Applying in vitro NMR spectroscopy and 1H NMR metabonomics to breast cancer characterization and detection. Prog. Nucl. Magn. Reson. Spectrosc. 2005, 47 (3-4), 165-74. 64. Rocha, C. M.; Barros, A. S.; Gil, A. M.; Goodfellow, B. J.; Humpfer, E.; Spraul, M.; Carreira, I. M.; Melo, J. B.; Bernardo, J.; Gomes, A.; Sousa, V.; Carvalho, L.; Duarte, I. F., Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J. Proteome Res. 2010, 9 (1), 319-32. 65. Vucenik, I.; Shamsuddin, A. K. M., Protection against cancer by dietary IP6 and inositol. Nutr. Cancer 2006, 55 (2), 109-25. 66. (a) Singh, R. P.; Agarwal, C.; Agarwal, R., Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003, 24 (3), 555-63; (b) Agarwal, C.; Dhanalakshmi, S.; Singh, R. P.; Agarwal, R., Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 2004, 6 (5), 646-59; (c) Vucenik, I.; Ramakrishna, G.; Tantivejkul, K.; Anderson, L. M.; Ramljak, D., Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCδ-dependent increase in p27 Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res. Treat. 2005, 91 (1), 35-45; (d) El-Sherbiny, Y. M.; Cox, M. C.; Ismail, Z. A.; Shamsuddin, A. M.; Vucenik, I., G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). Anticancer Res. 2001, 21 (4A), 2393-403. 67. Nigam, V. N.; MacDonald, H. L.; Cantero, A., Limiting factors for glycogen storage in tumors. Cancer Res. 1962, 22 (2), 131-8. 68. (a) Lee, M. K.; Kim, J. H.; Lee, C. H.; Kim, J. M.; Kang, C. D.; Kim, Y. D.; Choi, K. U.; Kim, H. W.; Kim, J. Y.; Park, D. Y., Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival. Pathology 2006, 38 (6), 555-60; (b) Schnier, J. B.; Nishi, K.; Gumerlock, P. H.; Gorin, F. A.; Bradbury, E. M., Glycogen synthesis correlates with androgen-dependent growth arrest in prostate cancer. BMC Urology 2005, 5 (1), 6. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6537 | - |
dc.description.abstract | 先前的研究發現ATP合成酶在多種癌細胞的細胞膜上表現,使用ATP合成酶抑制劑黃綠青黴素(citreoviridin)可以在不影響正常細胞下,而抑制肺癌細胞增生與腫瘤生長。由於在體內抑制表面型ATP合成酶的整體影響仍未清楚,因此在本研究中我們以相對和絕對定量的等量異位標籤(isobaric tags for relative and absolute quantitation, iTRAQ)定量蛋白質體學來分析citreoviridin在肺癌異種移植(xenograft)模式中的調控。我們以良好的再現性鑑定並定量了2,659個蛋白質,並且以它們在控制組與citreoviridin處理組的相對表現量挑選出表現量有差異的141個蛋白質。使用生物資訊學方法加以分析表現量有差異的蛋白質,結果發現在肺癌中citreoviridin會改變與葡萄糖代謝相關酵素的表現。參與糖質新生(gluconeogenesis)與葡萄糖儲存的酵素表現量增加,顯示citreoviridin可能藉由降低提供給合成巨分子所需的糖解作用中間產物來達到抑制癌細胞增生的效果。本研究以蛋白質體學探討citreoviridin抗肺癌作用可能影響代謝的功能,根據此研究結果,我們希望能有助於深入了解代謝與腫瘤生成的關係,並提供肺癌治療的策略方向。 | zh_TW |
dc.description.abstract | ATP synthase is present on the plasma membrane of several types of cancer cells. Citreoviridin, an ATP synthase inhibitor, selectively suppresses the proliferation and tumor growth of lung cancer without affecting normal cells. However, the global effects of targeting ectopic ATP synthase in vivo have not been well defined. In this study, we performed quantitative proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ) and provided a comprehensive insight into the complicated regulation by citreoviridin in lung cancer xenograft model. With high reproducibility of the quantitation, we obtained quantitative proteomic profiling with 2,659 proteins identified. Bioinformatics analysis of the 141 differentially expressed proteins selected by their relative abundance revealed that citreoviridin induces alterations in the expression of glucose metabolism-related enzymes in lung cancer. The up-regulation of enzymes involved in gluconeogenesis and storage of glucose indicated that citreoviridin may reduce the glycolytic intermediates for macromolecule synthesis and inhibit cell proliferation. The results provide metabolic aspects from comprehensive proteomics for the antitumorigenic effect of citreoviridin in lung cancer, which may lead to a better understanding of the links between metabolism and tumorigenesis in cancer therapy. | en |
dc.description.provenance | Made available in DSpace on 2021-05-17T09:14:30Z (GMT). No. of bitstreams: 1 ntu-101-R00b43009-1.pdf: 19077220 bytes, checksum: 9a79d51d59bff7f582507197c522f2dc (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書........................................I
誌謝........................................II 中文摘要........................................IV ABSTRACT........................................V CONTENTS........................................VI LIST OF FIGURES........................................XI LIST OF TABLES........................................XIV Chapter 1 Introduction........................................1 1.1 Lung cancer treatment........................................1 1.2 Ectopic ATP synthase........................................2 1.3 ATP synthase inhibitor citreoviridin........................................4 1.4 Proteomics........................................5 1.5 Quantitative proteomics by iTRAQ labeling........................................6 1.6 Cancer metabolism........................................8 1.7 Specific aims........................................10 1.8 Experimental design........................................11 Chapter 2 Materials and Methods........................................14 2.1 Reagents........................................14 2.2 Tumor tissues........................................15 2.3 Protein preparation........................................16 2.4 Reduction, alkylation and digestion of proteins........................................16 2.5 iTRAQ labeling of peptides........................................18 2.6 Strong cation exchange (SCX) chromatography........................................19 2.7 ZipTip desalting........................................19 2.8 LC-MS/MS analysis........................................20 2.9 Protein identification........................................21 2.10 Selecting peptides for quantitation........................................23 2.11 iTRAQ signal normalization........................................24 2.12 Protein quantitation........................................25 2.13 Selection of differentially expressed proteins........................................26 2.14 Integration of differentially expressed human proteins........................................29 2.15 Bioinformatics analysis........................................30 2.16 Western blotting........................................31 Chapter 3 Results........................................34 3.1 Reproducibility assessment by analysis of iTRAQ duplicate experiment........................................34 3.2 Proteomic profiling of citreoviridin-treated tumors........................................35 3.3 Optimization of peptide iTRAQ signal normalization........................................37 3.4 Quantitation of protein expression by iTRAQ signals........................................40 3.5 Cut-off value calculation for selecting differentially expressed proteins........................................41 3.6 Bioinformatics analysis of human differential proteomic profiling induced by citreoviridin........................................44 3.7 Validation of citreoviridin-induced gluconeogenesis in lung cancer xenograft tumors........................................47 Chapter 4 Discussion........................................49 4.1 Protein inference of xenograft........................................49 4.2 Protein abundance ratio calculation........................................50 4.3 The occurrence of gluconeogenesis........................................51 4.4 The effect on glucose metabolism by targeting ectopic ATP synthase........................................54 4.5 The antitumorigenic potential of metabolic therapy........................................56 Chapter 5 Conclusion........................................62 Chapter 6 Future work........................................63 REFERENCES........................................65 Figures........................................82 Tables........................................111 APPENDIX A........................................133 Appendix A1 Seven different normalization methods........................................133 APPENDIX B........................................137 Appendix B1 The proteomic data of the duplicate experiment........................................137 Appendix B2 The proteomic data of the small-scale experiment........................................137 Appendix B3 The proteomic data of the large-scale experiment........................................137 Appendix B4 The normalized data of duplicate experiment by seven different normalization methods........................................138 Appendix B5 The normalized data of large-scale experiment by normalization method 1 and method 2........................................138 Appendix B6 Calculation of cut-off values and estimation of individual variations among biological replicate of samples........................................139 Appendix B7 The results of Gene Ontology biological process clustering enrichment analysis........................................139 Appendix B8 The results of pathway map analysis and network analysis........................................139 APPENDIX C........................................141 Protocol: iTRAQ quantitative proteomics.........................................142 APPENDIX D........................................162 Posters........................................162 | |
dc.language.iso | en | |
dc.title | 以蛋白質體學探討ATP合成酶抑制劑在肺癌異種移植模式的作用 | zh_TW |
dc.title | Proteomic analysis reveals the effect of targeting ectopic ATP synthase by citreoviridin in lung cancer xenograft model | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李文雄,陳玉如,陳水田,黃宣誠 | |
dc.subject.keyword | 蛋白質體學,相對和絕對定量的等量異位標籤(iTRAQ),表面型ATP合成酶,肺癌,糖質新生, | zh_TW |
dc.subject.keyword | proteomics,iTRAQ,ectopic ATP synthase,lung cancer,gluconeogenesis, | en |
dc.relation.page | 169 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2012-08-16 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 分子與細胞生物學研究所 | zh_TW |
顯示於系所單位: | 分子與細胞生物學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf | 18.63 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。